EMILIN2: A Potential Drug Target and Biomarker (G84034)

Target Name: EMILIN2

NCBI ID: G84034

EMILIN2

EMILIN2: A Potential Drug Target and Biomarker

EMILIN2, also known as OTTHUMP00000158648, is a gene that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. Its unique genetic makeup and expression patterns have made it an attractive target for researchers to investigate, and potentially, develop new treatments.

EMILIN2 is a non-coding RNA molecule that is expressed in various tissues and organs throughout the body. It is a key regulator of the immune response and has been involved in the regulation of inflammation, immune cell proliferation, and tissue repair. EMILIN2 has also been shown to play a role in the development and progression of various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases.

One of the key features of EMILIN2 is its unique expression pattern. Unlike many genes, EMILIN2 is not expressed in all tissues and organs. Instead, it is primarily expressed in the brain and spinal cord, with lower levels of expression in other tissues. This specific expression pattern makes it an attractive target for drugs that can specifically target the brain and spinal cord, rather than the rest of the body.

EMILIN2 has also been shown to play a role in the regulation of immune cell function. Studies have shown that EMILIN2 can inhibit the activity of T-cells, a type of immune cell that play a critical role in fighting off infections and cancer. This suggests that EMILIN2 may be a useful target for drugs that are designed to enhance the immune response against diseases.

Another potential mechanism by which EMILIN2 may be involved in the development of diseases is its role in the regulation of cell death. Studies have shown that EMILIN2 can promote the survival of damaged cells, which may contribute to the development and progression of diseases. This suggests that EMILIN2 may be a useful target for drugs that are designed to prevent or reverse cell death in damaged tissues.

In addition to its potential as a drug target, EMILIN2 has also been shown to be a potential biomarker for various diseases. Studies have shown that EMILIN2 levels are often elevated in the brains and spinal cords of individuals with a variety of diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. This suggests that EMILIN2 may be a useful biomarker for these diseases, and that its levels can be used as a diagnostic tool.

Overall, EMILIN2 is a promising target for drugs that are designed to treat a variety of diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. Its unique expression pattern and role in the regulation of immune cell function make it an attractive candidate for drug development, and its potential as a biomarker for diseases adds to its potential clinical applications. Further research is needed to fully understand the role of EMILIN2 in the development and progression of diseases, and to develop safe and effective treatments.

Protein Name: Elastin Microfibril Interfacer 2

Functions: May be responsible for anchoring smooth muscle cells to elastic fibers, and may be involved not only in the formation of the elastic fiber, but also in the processes that regulate vessel assembly. Has cell adhesive capacity

The "EMILIN2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EMILIN2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets